

Heron Therapeutics Announces Commercial Leadership Changes



Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care announced changes to its commercial leadership team, including the appointment of Jason Grillot as Vice President, Sales and Marketing, Acute Care, effective April 24, 2023. Mr. Grillot brings more than two decades of hospital experience, most recently serving as a senior sales executive at CHIESI USA.

In addition, John Poyhonen, Heron's President and Chief Commercial Officer, and Michael Mathews, Heron's Senior Vice President Commercial, Acute Care, will cease to serve in their positions as of April 30, 2023. Following the departures of Mr. Poyhonen and Mr. Mathews, Craig Collard, Heron's Chief Executive Officer, will oversee Heron's commercial organization.

"I have had the pleasure of previously working closely with Jason. Since then, his leadership and sales track record in the hospital setting have been outstanding and I look forward to his contributions as we grow our acute care franchise," said Craig Collard. "In addition, I am excited to oversee the commercial group and focus on delivering increased value to the patients we serve, our customers and shareholders."

"I am excited to work with Craig again and the accomplished team at Heron to advance the acute care franchise," said Mr. Grillot. "I believe that ZYNRELEF[®] and APONVIE[™] have significant potential, and I look forward to addressing the two most common concerns for patients and clinicians after surgery, pain and nausea and vomiting."

In connection with the commencement of Mr. Grillot's employment, Heron will grant Mr. Grillot an option to purchase 350,000 shares of Heron common stock with an exercise price based on the closing price per share as reported on the Nasdaq Capital Market as of April 24, 2023, the effective date of the grant and the start date of Mr. Grillot's employment. The options are non-qualified stock options and have a 10-year term with a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% vesting on a monthly basis over the next three years, subject to Mr. Grillot's continuous service through each vesting date. In accordance with Nasdaq Listing Rule 5635(c)(4), this award was approved by Heron's Compensation Committee of the Board of Directors and made as a material inducement to Mr. Grillot entering into employment with Heron.

Source: [Heron Therapeutics, Inc.](#)

Published on : Thu, 20 Apr 2023